These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22491736)

  • 1. A molecular and computational diagnostic approach identifies FOXP3, ICOS, CD52 and CASP1 as the most informative biomarkers in acute graft-versus-host disease.
    Cuzzola M; Fiasché M; Iacopino P; Messina G; Martino M; Console G; Fedele R; Massi D; Recchia AG; Irrera G; Morabito F
    Haematologica; 2012 Oct; 97(10):1532-8. PubMed ID: 22491736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation between costimulatory molecule polymorphism and hepatitis B infections in hematopoietic stem cell transplant recipients.
    Yaghobi R; Saadi MI; Karimi MH; Geramizadeh B; Ramzi M; Zakerinia M
    Exp Clin Transplant; 2014 Aug; 12(4):357-66. PubMed ID: 24188429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation.
    Noriega V; Martínez-Laperche C; Buces E; Pion M; Sánchez-Hernández N; Martín-Antonio B; Guillem V; Bosch-Vizcaya A; Bento L; González-Rivera M; Balsalobre P; Kwon M; Serrano D; Gayoso J; de la Cámara R; Brunet S; Rojas-Contreras R; Nieto JB; Martínez C; Gónzalez M; Espigado I; Vallejo JC; Sampol A; Jiménez-Velasco A; Urbano-Ispizua A; Solano C; Gallardo D; Díez-Martín JL; Buño I;
    PLoS One; 2015; 10(10):e0140454. PubMed ID: 26473355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A T-Cell Surface Marker Panel Predicts Murine Acute Graft-Versus-Host Disease.
    Bäuerlein CA; Qureischi M; Mokhtari Z; Tabares P; Brede C; Jordán Garrote AL; Riedel SS; Chopra M; Reu S; Mottok A; Arellano-Viera E; Graf C; Kurzwart M; Schmiedgen K; Einsele H; Wölfl M; Schlegel PG; Beilhack A
    Front Immunol; 2020; 11():593321. PubMed ID: 33584657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Socié G; Loiseau P; Tamouza R; Janin A; Busson M; Gluckman E; Charron D
    Transplantation; 2001 Aug; 72(4):699-706. PubMed ID: 11544434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of FoxP3(+) regulatory T cells in the target tissues and blood in chronic graft versus host disease.
    Imanguli MM; Cowen EW; Rose J; Dhamala S; Swaim W; Lafond S; Yagi B; Gress RE; Pavletic SZ; Hakim FT
    Leukemia; 2014 Oct; 28(10):2016-27. PubMed ID: 24577531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma-based protein biomarkers can predict the risk of acute graft-versus-host disease and non-relapse mortality in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Shin J; Dan K; Han D; Kim JW; Kim KK; Koh Y; Shin DY; Hong J; Yoon SS; Park S; Song SH; Kim I
    Blood Cells Mol Dis; 2019 Feb; 74():5-12. PubMed ID: 30344086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Difference between FOXP3 gene expressions in donor grafts with or without acute graft-versus-host disease].
    Wang ZD; Feng SZ; Zhou SY; Wang M; Zhou Z; Zhai WJ; Han MZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1215-20. PubMed ID: 17204197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD52/GPI- T-Cells Are Enriched for Alloreactive Specificity and Predict Acute Graft-Versus-Host-Disease After Stem Cell Transplantation.
    Kinsella FA; Inman CF; Croft W; Zuo J; Pearce H; Barbieri S; Craddock C; Malladi R; Moss P
    Transplant Cell Ther; 2021 Jun; 27(6):475.e1-475.e9. PubMed ID: 33863699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation.
    Hosseini E; Schwarer AP; Ghasemzadeh M
    Iran J Allergy Asthma Immunol; 2012 Mar; 11(1):15-21. PubMed ID: 22427472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics.
    Khouri IF; Albitar M; Saliba RM; Ippoliti C; Ma YC; Keating MJ; Champlin RE
    Bone Marrow Transplant; 2004 Apr; 33(8):833-7. PubMed ID: 14755312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic risk factors for sclerotic graft-versus-host disease.
    Inamoto Y; Martin PJ; Flowers ME; Lee SJ; Carpenter PA; Warren EH; Geraghty DE; Lee N; Boeckh MJ; Storer BE; Levine DM; Fan W; Zhao LP; Hansen JA
    Blood; 2016 Sep; 128(11):1516-24. PubMed ID: 27313329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
    Ratzinger G; Reagan JL; Heller G; Busam KJ; Young JW
    Blood; 2003 Feb; 101(4):1422-9. PubMed ID: 12393688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphism of costimulatory molecules (CTLA4, ICOS, PD.1 and CD28) and allogeneic hematopoietic stem cell transplantation in Iranian patients.
    Iravani-Saadi M; Karimi MH; Yaghobi R; Geramizadeh B; Ramzi M; Niknam A; Pourfathollah A
    Immunol Invest; 2014; 43(4):391-404. PubMed ID: 24564845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers for acute and chronic graft-versus-host disease in regulatory T cells.
    Ukena SN; Geffers R; Buchholz S; Stadler M; Franzke A
    Transpl Immunol; 2012 Dec; 27(4):179-83. PubMed ID: 22889700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab for the prevention and treatment of graft-versus-host disease.
    Kanda J; Lopez RD; Rizzieri DA
    Int J Hematol; 2011 May; 93(5):586-593. PubMed ID: 21369856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation.
    Gimondi S; Dugo M; Vendramin A; Bermema A; Biancon G; Cavané A; Corradini P; Carniti C
    Exp Hematol; 2016 Jul; 44(7):624-634.e1. PubMed ID: 27013207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inducible Costimulator Gene-Transduced Bone Marrow-Derived Mesenchymal Stem Cells Attenuate the Severity of Acute Graft-Versus-Host Disease in Mouse Models.
    Yang D; Wang LP; Zhou H; Cheng H; Bao XC; Xu S; Zhang WP; Wang JM
    Cell Transplant; 2015; 24(9):1717-31. PubMed ID: 25203502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-dimensional structure discrepancy between HLA alleles for effective prediction of aGVHD severity and optimal selection of recipient-donor pairs: a proof-of-concept study.
    Han H; Yuan F; Sun Y; Liu J; Liu S; Luo Y; Liang F; Liu N; Long J; Zhao X; Kong F; Xi Y
    Oncotarget; 2015 Nov; 6(37):40337-59. PubMed ID: 26498683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.